BPA
RXRX icon

Beacon Pointe Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Beacon Pointe Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Buy
+10,734
New +$35.7K ﹤0.01% 1900

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Beacon Pointe Advisors's RXRX Position: Q2 2026 in Review

Beacon Pointe Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 10,734 shares worth $39.4K. The stake represents ﹤0.01% of the portfolio and ranks #1900 among its holdings.

342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Beacon Pointe Advisors held 10,734 shares of Recursion Pharmaceuticals worth $39.4K as of Q2 2026.
  • Recursion Pharmaceuticals was a new Beacon Pointe Advisors position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1900 holding.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.